

THRU ONLINE FILING

June 20, 2017

BSE Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,

**Sub: Clarification on US FDA communication on Company's Active Pharmaceuticals
Ingredients (APIs) and Formulations manufacturing units**

Further to our letters dated 15th June, 2017 regarding US FDA update on Company's Active Pharmaceutical Ingredients (APIs) manufacturing unit situated at Ratlam (Madhya Pradesh) and Formulations manufacturing units situated at SEZ Indore (Pithampur) and Piparia (Silvassa), we wish to inform you that our representative enquired with US FDA the reasons for their recent letters to the Company's above manufacturing units.


US FDA clarified that the reason for issuing these letters is for withdrawal of exemption on certain drugs which was due to the change in drug shortage situation in the US market.

We also wish to further clarify that US FDA has not carried out any new inspection / re-inspection of Company's above manufacturing units.

The Company remains fully committed in resolving the US FDA issues at the earliest. The Company is also committed to its philosophy of highest quality in manufacturing, operations, systems, integrity and cGMP culture.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com | CIN: L24239MH1949PLC007837